Search

Displaying results 2671 - 2680 of 4345 in total
  1. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    PF-07304814 is a small molecule prodrug that targets the 3CL<sup>pro</sup> protease (M<sup>pro)</sup>, which is used by viruses like SARS-CoV-2 to assemble and multiply[L31718]. … PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled[L31728].

  2. Drug

    PIKA rabies vaccine

    go.drugbank.com/drugs/DB17963
    Investigational

    PIKA rabies vaccine is a novel vaccine developed by YS Biopharma.

  3. Drug

    2G7

    go.drugbank.com/drugs/DB18589
    Experimental

    2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.

  4. Drug

    BB 21217

    go.drugbank.com/drugs/DB17373
    Investigational

    BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP

  5. Drug

    Orciprenaline

    go.drugbank.com/drugs/DB00816
    Approved

    A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]

    Products: Alupent Tab 20mg, Alupent Liq 50mg/ml
  6. Drug

    Udenafil

    go.drugbank.com/drugs/DB06267
    Approved

    Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., ...

  7. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlo...

  8. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  9. Drug

    BCL-005

    go.drugbank.com/drugs/DB17242
    Experimental

    BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells.

  10. Drug

    Piperidione

    go.drugbank.com/drugs/DB13224
    Experimental

    Piperidione was cough medicine marketed by Roche under the trade name Sedulon.